257 related articles for article (PubMed ID: 33540821)
1. MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer.
Huot JR; Pin F; Essex AL; Bonetto A
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540821
[TBL] [Abstract][Full Text] [Related]
2. HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia.
Huot JR; Novinger LJ; Pin F; Bonetto A
Dis Model Mech; 2020 Jan; 13(1):. PubMed ID: 31915140
[TBL] [Abstract][Full Text] [Related]
3. Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.
Huot JR; Novinger LJ; Pin F; Narasimhan A; Zimmers TA; O'Connell TM; Bonetto A
JCI Insight; 2020 May; 5(9):. PubMed ID: 32298240
[TBL] [Abstract][Full Text] [Related]
4. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
5. Physiological characterization of a mouse model of cachexia in colorectal liver metastases.
Murphy KT; Struk A; Malcontenti-Wilson C; Christophi C; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(10):R854-64. PubMed ID: 23485871
[TBL] [Abstract][Full Text] [Related]
6. Cancer cachexia decreases specific force and accelerates fatigue in limb muscle.
Roberts BM; Frye GS; Ahn B; Ferreira LF; Judge AR
Biochem Biophys Res Commun; 2013 Jun; 435(3):488-92. PubMed ID: 23673294
[TBL] [Abstract][Full Text] [Related]
7. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
9. Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia.
Pin F; Barreto R; Kitase Y; Mitra S; Erne CE; Novinger LJ; Zimmers TA; Couch ME; Bonewald LF; Bonetto A
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):685-700. PubMed ID: 30009406
[TBL] [Abstract][Full Text] [Related]
10. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice.
Murphy KT; Chee A; Gleeson BG; Naim T; Swiderski K; Koopman R; Lynch GS
Am J Physiol Regul Integr Comp Physiol; 2011 Sep; 301(3):R716-26. PubMed ID: 21677277
[TBL] [Abstract][Full Text] [Related]
11. Eccentric contraction-induced myofiber growth in tumor-bearing mice.
Hardee JP; Mangum JE; Gao S; Sato S; Hetzler KL; Puppa MJ; Fix DK; Carson JA
J Appl Physiol (1985); 2016 Jan; 120(1):29-37. PubMed ID: 26494443
[TBL] [Abstract][Full Text] [Related]
12. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
13. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
14. Metastatic or xenograft colorectal cancer models induce divergent anabolic deficits and expression of pro-inflammatory effectors of muscle wasting in a tumor-type-dependent manner.
Kim HG; Huot JR; Pin F; Belcher DJ; Bonetto A; Nader GA
J Appl Physiol (1985); 2022 Dec; 133(6):1273-1283. PubMed ID: 36201323
[TBL] [Abstract][Full Text] [Related]
15. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse.
Aulino P; Berardi E; Cardillo VM; Rizzuto E; Perniconi B; Ramina C; Padula F; Spugnini EP; Baldi A; Faiola F; Adamo S; Coletti D
BMC Cancer; 2010 Jul; 10():363. PubMed ID: 20615237
[TBL] [Abstract][Full Text] [Related]
16. PGC1α overexpression preserves muscle mass and function in cisplatin-induced cachexia.
Huot JR; Pin F; Chatterjee R; Bonetto A
J Cachexia Sarcopenia Muscle; 2022 Oct; 13(5):2480-2491. PubMed ID: 35903870
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia.
Conte E; Camerino GM; Mele A; De Bellis M; Pierno S; Rana F; Fonzino A; Caloiero R; Rizzi L; Bresciani E; Ben Haj Salah K; Fehrentz JA; Martinez J; Giustino A; Mariggiò MA; Coluccia M; Tricarico D; Lograno MD; De Luca A; Torsello A; Conte D; Liantonio A
J Cachexia Sarcopenia Muscle; 2017 Jun; 8(3):386-404. PubMed ID: 28294567
[TBL] [Abstract][Full Text] [Related]
18. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
Penna F; Bonetto A; Muscaritoli M; Costamagna D; Minero VG; Bonelli G; Rossi Fanelli F; Baccino FM; Costelli P
Int J Cancer; 2010 Oct; 127(7):1706-17. PubMed ID: 20039316
[TBL] [Abstract][Full Text] [Related]
19. IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway.
Ying L; Yao Y; Lv H; Lu G; Zhang Q; Yang Y; Zhou J
Am J Physiol Cell Physiol; 2022 May; 322(5):C814-C824. PubMed ID: 35319902
[TBL] [Abstract][Full Text] [Related]
20. Sex differences in skeletal muscle alterations in a model of colorectal cancer.
Greenman AC; Albrecht DM; Halberg RB; Diffee GM
Physiol Rep; 2020 Mar; 8(5):e14391. PubMed ID: 32170841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
